Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoon, J.-T.
Right arrow Articles by Weinstein, I. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoon, J.-T.
Right arrow Articles by Weinstein, I. B.
Vol. 1, 393-404, April 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

CP248, a Derivative of Exisulind, Causes Growth Inhibition, Mitotic Arrest, and Abnormalities in Microtubule Polymerization in Glioma Cells 1

Jung-Taek Yoon, Alexander F. Palazzo, Danhua Xiao, Thomas M. Delohery, Peter E. Warburton, Jeffrey N. Bruce, W. Joseph Thompson, Gerhard Sperl, Clark Whitehead, John Fetter, Rifat Pamukcu, Gregg G. Gundersen and I. Bernard Weinstein2

Herbert Irving Comprehensive Cancer Center [J-T. Y., D. X., I. B. W.], Department of Anatomy and Cell Biology [A. F. P., G. G. G.], Department of Neurological Surgery [J. N. B], College of Physicians and Surgeons, Columbia University, New York, NY 10032; Flow Cytometry Core Facility, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [T. M. D.]; Department of Human Genetics, Mount Sinai School of Medicine, New York, New York 10029 [P. E. W]; and Cell Pathways Inc., Horsham, Pennsylvania 19044 [W. J. T., G. S., C. W., J. F., R. P.]

Exisulind (sulindac sulfone) and two potent derivatives, CP248 and CP461, have been shown previously to cause growth inhibition and apoptosis in several types of human carcinoma cell lines. These and related compounds have not been previously studied with respect to glioma cell lines. In the present study, we found that these three compounds caused marked growth inhibition in four rat glioma and eight human glioma cell lines, with IC50 values of 150, 1, and 0.075 µM, respectively. When studied at these concentrations exisulind and CP461 had no significant effect on the cell cycle profile of glioma cells, but CP248 caused marked arrest in mitosis. Detailed studies of CP248 in the 9L rat gliosarcoma cell line indicated that treatment with 0.075 µM CP248 caused abnormalities in the spindle apparatus and activation of the spindle assembly check point. In interphase glioma cells, CP248 stabilized microtubules (MTs) at low concentrations (0.075 µM) and depolymerized MTs at higher concentrations (0.2–0.4 µM). In NIH 3T3 fibroblasts, 0.1 µM CP248 caused extensive MT depolymerization. CP248 also caused MT depolymerization when added to assembled MTs in vitro, which indicated that it can directly affect MTs, perhaps because it shares certain structural similarities with Colcemid. In glioma cells, the effects of CP248 on MTs were independent of the previously reported effects of this compound on activation of protein kinase G. Therefore, CP248 is a novel MT-active agent that may be useful in the treatment of glioblastoma, and possibly other types of cancer, because of its dual effects on protein kinase G and MTs.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
D. Xiao, A. Deguchi, G. G. Gundersen, B. Oehlen, L. Arnold, and I. B. Weinstein
The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization
Mol. Cancer Ther., January 1, 2006; 5(1): 60 - 67.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
B. Zhu, S. Strada, and T. Stevens
Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells
Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L196 - L206.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. E. Witta, D. L. Gustafson, A. S. Pierson, A. Menter, S. N. Holden, M. Basche, M. Persky, C. L. O'Bryant, C. Zeng, A. Baron, et al.
A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors
Clin. Cancer Res., November 1, 2004; 10(21): 7229 - 7237.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Xiao, J. T. Pinto, J.-W. Soh, A. Deguchi, G. G. Gundersen, A. F. Palazzo, J.-T. Yoon, H. Shirin, and I. B. Weinstein
Induction of Apoptosis by the Garlic-Derived Compound S-Allylmercaptocysteine (SAMC) Is Associated with Microtubule Depolymerization and c-Jun NH2-Terminal Kinase 1 Activation
Cancer Res., October 15, 2003; 63(20): 6825 - 6837.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.